Drug Type Synthetic peptide |
Synonyms- |
Target |
Action agonists |
Mechanism PTH1R agonists(Parathyroid hormone receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoporosis, Postmenopausal | Phase 3 | United States | 05 Aug 2019 |
Phase 2 | 250 | (Abaloparatide Transdermal (50 mcg)) | gkzydhheov(jrghsaszlb) = rytyqswhrb hqapaavnnr (sltbdsubuo, 2.87) View more | - | 19 Dec 2016 | ||
(Abaloparatide Transdermal (100 mcg)) | gkzydhheov(jrghsaszlb) = geqjmerrye hqapaavnnr (sltbdsubuo, 2.96) View more |






